MUMBAI, March 20 — A deluge of weight-loss drugs is set to transform the global fight against obesity as India prepares to unleash low-cost generic versions of injections like...
and enjoy FREE RM10 & when you sign up using code VERSAMM10 with min. cash of RM100 today! T&Cs apply.MUMBAI, March 20 — A deluge of weight-loss drugs is set to transform the global fight against obesity as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent expired today.
The move will dramatically widen access to treatments that have long been considered a luxury, especially in middle-income countries, where soaring demand has collided with steep prices.More than 50 people walk into endocrinologist Nadeem Rais’s office every week seeking weight-loss injections.“When generics come out and prices drop, that could go up to 200 easily.” His colleague Sunera Ghai agrees saying that demand is “very high” but many “probably aren’t taking it just because it is truly a luxury item at this point”. A medicine distributor displays a pack of Ozempic self-injecting GLP-1 prefilled pens at his office in Thane on March 20, 2026. — AFP pic The breakthrough comes as patents on semaglutide — the active ingredient in drugs such as Ozempic and Wegovy — expired today in India, the world’s largest supplier of generic medicines. By the end of 2026, core patents on semaglutide will have expired in 10 countries that represent 48 per cent of the global obesity burden, according to a study published earlier this month by researchers.For India’s drug giants, this marks the start of an aggressive new race. At least four major firms have already prepared generic semaglutide injections, regulatory filings and compliance documents viewed by AFP show. Some, including Zydus Lifesciences, have announced “Day 1” launches, suggesting generic versions may become available as soon as this weekend in India.“What we understand is, there will be more than 50 brands that will be launched in the market and there are more than 40 players who will be launching these drugs,” Pharmarack’s vice president Sheetal Sapale said.This photograph taken on March 17, 2026 shows obesity doctor and consultant Swati Pradhan explaining a body mass index chart at her clinic in Mumbai. — AFP pic While the country still accounts for a third of the world’s undernutrition according to the World Health Organization , rising incomes and urban lifestyles have pushed obesity rates sharply upward. Government data released March last year shows 24 per cent of women and 23 per cent of men are overweight or obese in India. “Once a person starts earning money, he becomes more sedentary here,” says bariatric surgeon Sanjay Borude. “While in first-world countries, the more the money, they become more active and devote time for their health, this is reversed in India.” These flipped economics have worked well for big pharma players like Eli Lilly and Novo Nordisk who have been cashing in on the market. India’s weight-loss drug sales have grown tenfold in five years to US$153 million as of 2026, and are projected to soar to over half a billion by 2030.Breaking price barrier Eli Lilly’s Mounjaro became the country’s top-selling drug by value last year, surpassing even common antibiotics. Still, high prices — often 15,000 to 22,000 rupees a month — limit access, says Swati Pradhan, who runs a weight-loss clinic in Mumbai. She expects patient numbers to rise once generics push treatment costs closer to 5,000 rupees a month. This photograph taken on March 17, 2026 shows obesity doctor and consultant Swati Pradhan explaining a body mass index chart at her clinic in Mumbai. — AFP picIndia supplies more than half of Africa’s generic medicines, and cheaper semaglutide could become a lifeline for countries where obesity is rising rapidly but treatment remains unaffordable. “Lower-cost semaglutide could significantly expand access to effective treatment particularly in middle-income countries where price has been a major barrier,” Simon Barquera, president of the World Obesity Federation, told AFP. “But medication alone will not reverse the global rise in obesity. Obesity is a complex, chronic disease,” he said, noting the importance of prevention efforts and healthier environments. Indian firms will be a key driving force, with Dr Reddy’s Laboratories aiming to launch its version of semaglutide in Canada by May 2026. For patients like 46-year-old Sukant Mangal, who lost nearly 30 pounds in eight months, wider access could not come soon enough. Many he knows simply abandoned treatment mid-way when they realised they would have to spend 20,000 rupees a month for seven to eight months.
Ozempic Generic Launch Semaglutide Patent Expiry India Weight-Loss Drugs Low-Cost Obesity Medication Global Obesity Fight
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Goods, logistics vehicles banned from roads during Hari Raya on March 19-20, 28-29The 55-year-old received praise for always making time for his friends, regardless of their background or social status.
Read more »
Bursa Malaysia, subsidiaries to close March 20–23 for Hari Raya AidilfitriKUALA LUMPUR, March 18 — Bursa Malaysia and its subsidiaries will be closed from Friday to Monday (March 20-23, 2026) in conjunction with the upcoming Hari Raya Aidilfitri public...
Read more »
Karachi battered by rare March storms as heavy rain, wind claim at least 18 livesKARACHI, March 19 — Heavy rain and strong winds left at least 18 people dead in Pakistan’s financial capital Karachi, city authorities and rescue services said...
Read more »
Singapore Muslims to Celebrate Hari Raya Aidilfitri on March 21Singapore's Islamic leader announced that Hari Raya Aidilfitri will be celebrated on Saturday, March 21, as the crescent moon was not sighted. The Mufti encouraged Muslims to continue with good deeds and prayers before Syawal.
Read more »
Southeast Asian Nations to Celebrate Aidilfitri on March 21st Following Crescent Moon ObservationsSingapore, Indonesia, Thailand, and Cambodia to celebrate Aidilfitri on March 21st after crescent moon not sighted. Religious authorities across the region made announcements following the MABIMS criteria and astronomical data.
Read more »
Traffic smooth on major highways Friday (March 20) eveningMarch 19 (Reuters) - OpenAI is planning to unify its ChatGPT app, coding platform Codex and browser into a desktop 'superapp' to simplify user experience, the Wall Street Journal reported on Thursday.
Read more »